Elena Tovar Ambel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Tovar Ambel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aurelio Hernández-Laín
Department of Neuropathology, Hospital Universitario 12 de Octubre, Madrid, Spain
14 shared publications - Juan Manuel Sepúlveda-Sánchez
HM Sanchinarro University Hospital , Madrid
14 shared publications - Berta Segura-Collar
Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain
13 shared publications - Blanca Cómitre-Mariano
Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain
13 shared publications - Denisse Alcivar López
Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, Spain
13 shared publications - Javier Gutierrez-Martin
Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
13 shared publications
Latest Publications
- Open Access
- 15 August 2026
- Published by Elsevier in Neuroscience
- Vol. 614, 245-253
Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma
- 15 August 2026
- Published by Elsevier in Neuroscience
- Vol. 614, 245-253
Open AccessExploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S3. Characterization of TRIB2 expression in murine glioma models.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S3. Characterization of TRIB2 expression in murine glioma models.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Data from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment. However, it is still not known why GBM is characterized by an immune-cold tumor microenvironment with reduced CD8+ T-cell infiltration when there is substantial myeloid cell infiltration and a substantial alteration of the blood-brain barrier. The aim of this study was to identify regulators of low CD8+ T-cell infiltration in GBM. Using transcriptomic screening, we found that tribbles homolog 2 (TRIB2) is a regulator of the immune-cold microenvironment characteristic of GBM. Further analysis of a cohort of 114 brain tumors with IHC, RNA sequencing, and qRT-PCR showed that TRIB2 inhibited the transcription of genes involved in antigen presentation by the tumor cells and those involved in T-cell recruitment by modulating the expression of methylation regulators, in particular DNA methyltransferase 1. Further, we observed 75% survival after TRIB2 inhibition in murine glioma models and showed transcriptomic reprogramming by decitabine of genes involved in the processes described above. In our patient-derived tumor fragments assay, we observed a consistent, generalized response to decitabine, suggesting that DNA methyltransferase 1 inhibition (DNMT1) could be a promising therapeutic strategy for GBM.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment. However, it is still not known why GBM is characterized by an immune-cold tumor microenvironment with reduced CD8+ T-cell infiltration when there is substantial myeloid cell infiltration and a substantial alteration of the blood-brain barrier. The aim of this study was to identify regulators of low CD8+ T-cell infiltration in GBM. Using transcriptomic screening, we found that tribbles homolog 2 (TRIB2) is a regulator of the immune-cold microenvironment characteristic of GBM. Further analysis of a cohort of 114 brain tumors with IHC, RNA sequencing, and qRT-PCR showed that TRIB2 inhibited the transcription of genes involved in antigen presentation by the tumor cells and those involved in T-cell recruitment by modulating the expression of methylation regulators, in particular DNA methyltransferase 1. Further, we observed 75% survival after TRIB2 inhibition in murine glioma models and showed transcriptomic reprogramming by decitabine of genes involved in the processes described above. In our patient-derived tumor fragments assay, we observed a consistent, generalized response to decitabine, suggesting that DNA methyltransferase 1 inhibition (DNMT1) could be a promising therapeutic strategy for GBM.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S2. TRIB2 expression is associated with proliferation processes and vascular cells in GBM.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S2. TRIB2 expression is associated with proliferation processes and vascular cells in GBM.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S1. Genes highly expressed in GBM compared to BrM tumors.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S1. Genes highly expressed in GBM compared to BrM tumors.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S4. Molecular characterization of TRIB2-associated methyltransferases and their role in gene expression and immune regulation.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy
Supplementary figure S4. Molecular characterization of TRIB2-associated methyltransferases and their role in gene expression and immune regulation.